

References

1. Li, Q. & Barres, B. A. Microglia and macrophages in brain homeostasis and disease. *Nat. Rev. Immunol.* **18**, 225–242 (2018).
2. García-Marín, V., García-López, P. & Freire, M. Cajal's contributions to glia research. *Trends Neurosci.* **30**, 479–487 (2007).
3. Tremblay, M.-È., Lecours, C., Samson, L., Sánchez-Zafra, V. & Sierra, A. From the Cajal alumni Achúcarro and Río-Hortega to the rediscovery of never-resting microglia. *Front. Neuroanat.* **9**, 45 (2015).
4. Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. *Science* **308**, 1314–1318 (2005).
5. Li, Y., Du, X.-F., Liu, C.-S., Wen, Z.-L. & Du, J.-L. Reciprocal regulation between resting microglial dynamics and neuronal activity in vivo. *Dev. Cell* **23**, 1189–1202 (2012).
6. Muffat, J. *et al.* Efficient derivation of microglia-like cells from human pluripotent stem cells. *Nat. Med.* **22**, 1358–1367 (2016).
7. Ginhoux, F., Lim, S., Hoeffel, G., Low, D. & Huber, T. Origin and differentiation of microglia. *Front. Cell. Neurosci.* **7**, (2013).
8. Fujita, S. & Kitamura, T. Origin of brain macrophages and the nature of the so-called microglia. *Acta Neuropathol. Suppl.* **Suppl 6**, 291–296 (1975).
9. Kitamura, T., Miyake, T. & Fujita, S. Genesis of resting microglia in the gray matter of mouse hippocampus. *J. Comp. Neurol.* **226**, 421–433 (1984).
10. Hao, C., Richardson, A. & Fedoroff, S. Macrophage-like cells originate from neuroepithelium in culture: characterization and properties of the macrophage-like cells. *Int. J. Dev. Neurosci.* **9**, 1–14 (1991).
11. Murabe, Y. & Sano, Y. Morphological studies on neuroglia. VI. Postnatal development of microglial cells. *Cell Tissue Res.* **225**, 469–485 (1982).

12. Akiyama, H. & McGeer, P. L. Brain microglia constitutively express beta-2 integrins. *J. Neuroimmunol.* **30**, 81–93 (1990).
13. McKercher, S. R. *et al.* Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. *EMBO J.* **15**, 5647–5658 (1996).
14. Alliot, F., Godin, I. & Pessac, B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. *Brain Res. Dev. Brain Res.* **117**, 145–152 (1999).
15. Monier, A. *et al.* Entry and distribution of microglial cells in human embryonic and fetal cerebral cortex. *J. Neuropathol. Exp. Neurol.* **66**, 372–382 (2007).
16. De Kleer, I., Willems, F., Lambrecht, B. & Goriely, S. Ontogeny of myeloid cells. *Front. Immunol.* **5**, 423 (2014).
17. Ginhoux, F. *et al.* Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages. *Science* **330**, 841–845 (2010).
18. Gomez Perdiguero, E. *et al.* Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. *Nature* **518**, 547–551 (2015).
19. Schulz, C. *et al.* A lineage of myeloid cells independent of Myb and hematopoietic stem cells. *Science* **336**, 86–90 (2012).
20. Hoeffel, G. *et al.* C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. *Immunity* **42**, 665–678 (2015).
21. Kierdorf, K. *et al.* Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. *Nat. Neurosci.* **16**, 273–280 (2013).
22. Louveau, A., Harris, T. H. & Kipnis, J. Revisiting the Mechanisms of CNS Immune Privilege. *Trends Immunol.* **36**, 569–577 (2015).
23. Beers, D. R. *et al.* Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 16021–16026 (2006).
24. Kamran, P. *et al.* Parabiosis in mice: a detailed protocol. *J. Vis. Exp.* (2013)
doi:10.3791/50556.

25. Ajami, B., Bennett, J. L., Krieger, C., Tetzlaff, W. & Rossi, F. M. V. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. *Nat. Neurosci.* **10**, 1538–1543 (2007).
26. Hashimoto, D. *et al.* Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. *Immunity* **38**, 792–804 (2013).
27. Huang, Y. *et al.* Repopulated microglia are solely derived from the proliferation of residual microglia after acute depletion. *Nat. Neurosci.* **21**, 530–540 (2018).
28. Varvel, N. H. *et al.* Microglial repopulation model reveals a robust homeostatic process for replacing CNS myeloid cells. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 18150–18155 (2012).
29. Elmore, M. R. P. *et al.* Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. *Neuron* **82**, 380–397 (2014).
30. Kierdorf, K. & Prinz, M. Microglia in steady state. *J. Clin. Invest.* **127**, 3201–3209 (2017).
31. Salter, M. W. & Stevens, B. Microglia emerge as central players in brain disease. *Nat. Med.* **23**, 1018–1027 (2017).
32. Tay, T. L., Savage, J. C., Hui, C. W., Bisht, K. & Tremblay, M.-È. Microglia across the lifespan: from origin to function in brain development, plasticity and cognition. *J. Physiol.* **595**, 1929–1945 (2017).
33. Yin, J., Valin, K. L., Dixon, M. L. & Leavenworth, J. W. The Role of Microglia and Macrophages in CNS Homeostasis, Autoimmunity, and Cancer. *J Immunol Res* **2017**, 5150678 (2017).
34. Oosterhof, N. *et al.* Homozygous Mutations in CSF1R Cause a Pediatric-Onset Leukoencephalopathy and Can Result in Congenital Absence of Microglia. *Am. J. Hum. Genet.* **104**, 936–947 (2019).
35. Cunningham, C. L., Martínez-Cerdeño, V. & Noctor, S. C. Microglia regulate the number of neural precursor cells in the developing cerebral cortex. *J. Neurosci.* **33**, 4216–4233

- (2013).
36. Tronnes, A. A. *et al.* Effects of Lipopolysaccharide and Progesterone Exposures on Embryonic Cerebral Cortex Development in Mice. *Reprod. Sci.* **23**, 771–778 (2016).
 37. Ueno, M. *et al.* Layer V cortical neurons require microglial support for survival during postnatal development. *Nat. Neurosci.* **16**, 543–551 (2013).
 38. Frade, J. M. & Barde, Y. A. Microglia-derived nerve growth factor causes cell death in the developing retina. *Neuron* **20**, 35–41 (1998).
 39. Marín-Teva, J. L. *et al.* Microglia promote the death of developing Purkinje cells. *Neuron* **41**, 535–547 (2004).
 40. Wakselman, S. *et al.* Developmental neuronal death in hippocampus requires the microglial CD11b integrin and DAP12 immunoreceptor. *J. Neurosci.* **28**, 8138–8143 (2008).
 41. Rymo, S. F. *et al.* A two-way communication between microglial cells and angiogenic sprouts regulates angiogenesis in aortic ring cultures. *PLoS One* **6**, e15846 (2011).
 42. Schafer, D. P. *et al.* Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. *Neuron* **74**, 691–705 (2012).
 43. Paolicelli, R. C. *et al.* Synaptic pruning by microglia is necessary for normal brain development. *Science* **333**, 1456–1458 (2011).
 44. Stevens, B. *et al.* The classical complement cascade mediates CNS synapse elimination. *Cell* **131**, 1164–1178 (2007).
 45. Lui, H. *et al.* Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. *Cell* **165**, 921–935 (2016).
 46. Paolicelli, R. C., Bisht, K. & Tremblay, M.-È. Fractalkine regulation of microglial physiology and consequences on the brain and behavior. *Front. Cell. Neurosci.* **8**, 129 (2014).
 47. Rogers, J. T. *et al.* CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity. *J. Neurosci.* **31**, 16241–16250 (2011).

48. George, J., Cunha, R. A., Mulle, C. & Amédée, T. Microglia-derived purines modulate mossy fibre synaptic transmission and plasticity through P2X4 and A1 receptors. *Eur. J. Neurosci.* **43**, 1366–1378 (2016).
49. Sipe, G. O. *et al.* Microglial P2Y12 is necessary for synaptic plasticity in mouse visual cortex. *Nat. Commun.* **7**, 10905 (2016).
50. Baufeld, C., Osterloh, A., Prokop, S., Miller, K. R. & Heppner, F. L. High-fat diet-induced brain region-specific phenotypic spectrum of CNS resident microglia. *Acta Neuropathol.* **132**, 361–375 (2016).
51. Erny, D. *et al.* Host microbiota constantly control maturation and function of microglia in the CNS. *Nat. Neurosci.* **18**, 965–977 (2015).
52. Hammond, T. R., Robinton, D. & Stevens, B. Microglia and the Brain: Complementary Partners in Development and Disease. *Annu. Rev. Cell Dev. Biol.* **34**, 523–544 (2018).
53. Menon, D. K., Schwab, K., Wright, D. W., Maas, A. I. & Demographics and Clinical Assessment Working Group of the International and Interagency Initiative toward Common Data Elements for Research on Traumatic Brain Injury and Psychological Health. Position statement: definition of traumatic brain injury. *Arch. Phys. Med. Rehabil.* **91**, 1637–1640 (2010).
54. Davalos, D. *et al.* ATP mediates rapid microglial response to local brain injury in vivo. *Nat. Neurosci.* **8**, 752–758 (2005).
55. Roth, T. L. *et al.* Transcranial amelioration of inflammation and cell death after brain injury. *Nature* **505**, 223–228 (2014).
56. Lou, N. *et al.* Purinergic receptor P2RY12-dependent microglial closure of the injured blood-brain barrier. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 1074–1079 (2016).
57. Hsieh, C. L. *et al.* Traumatic brain injury induces macrophage subsets in the brain. *Eur. J. Immunol.* **43**, 2010–2022 (2013).
58. Smith, C. *et al.* The neuroinflammatory response in humans after traumatic brain injury. *Neuropathol. Appl. Neurobiol.* **39**, 654–666 (2013).

59. Ziebell, J. M. & Morganti-Kossmann, M. C. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. *Neurotherapeutics* **7**, 22–30 (2010).
60. Faden, A. I. & Loane, D. J. Chronic neurodegeneration after traumatic brain injury: Alzheimer disease, chronic traumatic encephalopathy, or persistent neuroinflammation? *Neurotherapeutics* **12**, 143–150 (2015).
61. Loane, D. J. & Kumar, A. Microglia in the TBI brain: The good, the bad, and the dysregulated. *Exp. Neurol.* **275 Pt 3**, 316–327 (2016).
62. Donat, C. K., Scott, G., Gentleman, S. M. & Sastre, M. Microglial Activation in Traumatic Brain Injury. *Front. Aging Neurosci.* **9**, 208 (2017).
63. Graham, N. S. & Sharp, D. J. Understanding neurodegeneration after traumatic brain injury: from mechanisms to clinical trials in dementia. *J. Neurol. Neurosurg. Psychiatry* **90**, 1221–1233 (2019).
64. Li, Y. *et al.* Head Injury as a Risk Factor for Dementia and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of 32 Observational Studies. *PLoS One* **12**, e0169650 (2017).
65. Bramlett, H. M., Kraydieh, S., Green, E. J. & Dietrich, W. D. Temporal and regional patterns of axonal damage following traumatic brain injury: a beta-amyloid precursor protein immunocytochemical study in rats. *J. Neuropathol. Exp. Neurol.* **56**, 1132–1141 (1997).
66. Franz, G. *et al.* Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. *Neurology* **60**, 1457–1461 (2003).
67. Goldman, S. M. *et al.* Head injury, α -synuclein Rep1, and Parkinson’s disease. *Ann. Neurol.* **71**, 40–48 (2012).
68. McKee, A. C. *et al.* The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. *Acta Neuropathol.* **131**, 75–86 (2016).

69. Xiong, Y., Mahmood, A. & Chopp, M. Current understanding of neuroinflammation after traumatic brain injury and cell-based therapeutic opportunities. *Chin. J. Traumatol.* **21**, 137–151 (2018).
70. Johnson, V. E. *et al.* Inflammation and white matter degeneration persist for years after a single traumatic brain injury. *Brain* **136**, 28–42 (2013).
71. Scott, G. *et al.* Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. *Brain* **141**, 459–471 (2018).
72. Li, L. *et al.* The Association Between Apolipoprotein E and Functional Outcome After Traumatic Brain Injury: A Meta-Analysis. *Medicine* **94**, e2028 (2015).
73. Lucchinetti, C. *et al.* Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. *Ann. Neurol.* **47**, 707–717 (2000).
74. Singh, S. *et al.* Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons. *Acta Neuropathol.* **125**, 595–608 (2013).
75. Ohl, K., Tenbrock, K. & Kipp, M. Oxidative stress in multiple sclerosis: Central and peripheral mode of action. *Exp. Neurol.* **277**, 58–67 (2016).
76. Gray, E., Thomas, T. L., Betmouni, S., Scolding, N. & Love, S. Elevated myeloperoxidase activity in white matter in multiple sclerosis. *Neurosci. Lett.* **444**, 195–198 (2008).
77. Fischer, M. T. *et al.* NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. *Brain* **135**, 886–899 (2012).
78. Centonze, D. *et al.* Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. *J. Neurosci.* **29**, 3442–3452 (2009).
79. Lampron, A. *et al.* Inefficient clearance of myelin debris by microglia impairs remyelinating processes. *J. Exp. Med.* **212**, 481–495 (2015).
80. Miron, V. E. *et al.* M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. *Nat. Neurosci.* **16**, 1211–1218 (2013).
81. Tetreault, N. A. *et al.* Microglia in the cerebral cortex in autism. *J. Autism Dev. Disord.*

- 42, 2569–2584 (2012).
82. Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W. & Pardo, C. A. Neuroglial activation and neuroinflammation in the brain of patients with autism. *Ann. Neurol.* **57**, 67–81 (2005).
 83. Morgan, J. T. *et al.* Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. *Biol. Psychiatry* **68**, 368–376 (2010).
 84. Suzuki, K. *et al.* Microglial activation in young adults with autism spectrum disorder. *JAMA Psychiatry* **70**, 49–58 (2013).
 85. Gupta, S. *et al.* Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. *Nat. Commun.* **5**, 5748 (2014).
 86. Voineagu, I. *et al.* Transcriptomic analysis of autistic brain reveals convergent molecular pathology. *Nature* **474**, 380–384 (2011).
 87. Feinberg, I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? *J. Psychiatr. Res.* **17**, 319–334 (1982).
 88. Penzes, P., Cahill, M. E., Jones, K. A., VanLeeuwen, J.-E. & Woolfrey, K. M. Dendritic spine pathology in neuropsychiatric disorders. *Nat. Neurosci.* **14**, 285–293 (2011).
 89. Gu, N. *et al.* Spinal Microgliosis Due to Resident Microglial Proliferation Is Required for Pain Hypersensitivity after Peripheral Nerve Injury. *Cell Rep.* **16**, 605–614 (2016).
 90. Okubo, M. *et al.* Macrophage-Colony Stimulating Factor Derived from Injured Primary Afferent Induces Proliferation of Spinal Microglia and Neuropathic Pain in Rats. *PLoS One* **11**, e0153375 (2016).
 91. Gu, N. *et al.* Microglial P2Y₁₂ receptors regulate microglial activation and surveillance during neuropathic pain. *Brain Behav. Immun.* **55**, 82–92 (2016).
 92. Guan, Z. *et al.* Injured sensory neuron-derived CSF1 induces microglial proliferation and DAP12-dependent pain. *Nat. Neurosci.* **19**, 94–101 (2016).
 93. Stelzmann, R. A., Norman Schnitzlein, H. & Reed Murtagh, F. An english translation of

- alzheimer's 1907 paper, ? über eine eigenartige erkankung der hirnrinde? *Clin. Anat.* **8**, 429–431 (1995).
94. Hippus, H. & Neundörfer, G. The discovery of Alzheimer's disease. *Dialogues Clin. Neurosci.* **5**, 101–108 (2003).
 95. Barber, R. C. The genetics of Alzheimer's disease. *Scientifica* **2012**, 246210 (2012).
 96. Davies, P. & Maloney, A. J. Selective loss of central cholinergic neurons in Alzheimer's disease. *Lancet* **2**, 1403 (1976).
 97. Francis, P. T., Palmer, A. M., Snape, M. & Wilcock, G. K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. *J. Neurol. Neurosurg. Psychiatry* **66**, 137–147 (1999).
 98. Liu, P.-P., Xie, Y., Meng, X.-Y. & Kang, J.-S. History and progress of hypotheses and clinical trials for Alzheimer's disease. *Signal Transduct Target Ther* **4**, 29 (2019).
 99. Hardy, J. A. & Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. *Science* **256**, 184–185 (1992).
 100. Goate, A. *et al.* Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* **349**, 704–706 (1991).
 101. Ryan, N. S. *et al.* Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series. *Lancet Neurol.* **15**, 1326–1335 (2016).
 102. Sherrington, R. *et al.* Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature* **375**, 754–760 (1995).
 103. Levy-Lahad, E. *et al.* Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science* **269**, 973–977 (1995).
 104. Ricciarelli, R. & Fedele, E. The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind. *Curr. Neuropharmacol.* **15**, 926–935 (2017).
 105. Mucke, L. & Selkoe, D. J. Neurotoxicity of amyloid β -protein: synaptic and network dysfunction. *Cold Spring Harb. Perspect. Med.* **2**, a006338 (2012).
 106. Ferreira, S. T., Lourenco, M. V., Oliveira, M. M. & De Felice, F. G. Soluble amyloid- β

- oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease. *Front. Cell. Neurosci.* **9**, 191 (2015).
107. Lorenzo, A. & Yankner, B. A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. *Proc. Natl. Acad. Sci. U. S. A.* **91**, 12243–12247 (1994).
108. Tomiyama, T. *et al.* A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. *J. Neurosci.* **30**, 4845–4856 (2010).
109. McLaurin, J. *et al.* Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. *Nat. Med.* **12**, 801–808 (2006).
110. Li, C., Ebrahimi, A. & Schluesener, H. Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease. *Ageing Res. Rev.* **12**, 116–140 (2013).
111. Reitz, C. Alzheimer's disease and the amyloid cascade hypothesis: a critical review. *Int. J. Alzheimers. Dis.* **2012**, 369808 (2012).
112. Armstrong, R. A. A critical analysis of the 'amyloid cascade hypothesis'. *Folia Neuropathol.* **52**, 211–225 (2014).
113. Mullard, A. Anti-amyloid failures stack up as Alzheimer antibody flops. *Nat. Rev. Drug Discov.* (2019) doi:10.1038/d41573-019-00064-1.
114. Miller, B. W., Willett, K. C. & Desilets, A. R. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. *Ann. Pharmacother.* **45**, 1416–1424 (2011).
115. Doody, R. S. *et al.* A phase 3 trial of semagacestat for treatment of Alzheimer's disease. *N. Engl. J. Med.* **369**, 341–350 (2013).
116. Barão, S., Moechars, D., Lichtenthaler, S. F. & De Strooper, B. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease. *Trends Neurosci.* **39**, 158–169 (2016).
117. Gilman, S. *et al.* Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. *Neurology* **64**, 1553–1562 (2005).
118. Salloway, S. *et al.* Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's

- disease. *N. Engl. J. Med.* **370**, 322–333 (2014).
119. Rinne, J. O. *et al.* 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. *Lancet Neurol.* **9**, 363–372 (2010).
120. Mehta, D., Jackson, R., Paul, G., Shi, J. & Sabbagh, M. Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015. *Expert Opin. Investig. Drugs* **26**, 735–739 (2017).
121. Abbott, A. Fresh push for 'failed' Alzheimer's drug. *Nature* (2019)
doi:10.1038/d41586-019-03261-5.
122. Kueper, J. K., Speechley, M. & Montero-Odasso, M. The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review. *J. Alzheimers. Dis.* **63**, 423–444 (2018).
123. Saunders, A. M. *et al.* Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. *Neurology* **43**, 1467–1472 (1993).
124. Strittmatter, W. J. *et al.* Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc. Natl. Acad. Sci. U. S. A.* **90**, 1977–1981 (1993).
125. Corder, E. H. *et al.* Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. *Nat. Genet.* **7**, 180–184 (1994).
126. Rogava, E. *et al.* The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. *Nat. Genet.* **39**, 168–177 (2007).
127. Bush, W. S. & Moore, J. H. Chapter 11: Genome-wide association studies. *PLoS Comput. Biol.* **8**, e1002822 (2012).
128. McGeer, P. L., Akiyama, H., Itagaki, S. & McGeer, E. G. Immune system response in Alzheimer's disease. *Can. J. Neurol. Sci.* **16**, 516–527 (1989).
129. Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S. & Selkoe, D. Relationship of microglia

- and astrocytes to amyloid deposits of Alzheimer disease. *J. Neuroimmunol.* **24**, 173–182 (1989).
130. Sims, R. *et al.* Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nat. Genet.* **49**, 1373–1384 (2017).
131. Harold, D. *et al.* Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat. Genet.* **41**, 1088–1093 (2009).
132. Jun, G. *et al.* Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. *Arch. Neurol.* **67**, 1473–1484 (2010).
133. Seshadri, S. *et al.* Genome-wide analysis of genetic loci associated with Alzheimer disease. *JAMA* **303**, 1832–1840 (2010).
134. Kunkle, B. W. *et al.* Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat. Genet.* **51**, 414–430 (2019).
135. Lambert, J. C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat. Genet.* **45**, 1452–1458 (2013).
136. Marioni, R. E. *et al.* GWAS on family history of Alzheimer's disease. *Transl. Psychiatry* **8**, 99 (2018).
137. Jansen, I. E. *et al.* Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nat. Genet.* **51**, 404–413 (2019).
138. Lambert, J.-C. *et al.* Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat. Genet.* **41**, 1094–1099 (2009).
139. Hollingworth, P. *et al.* Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat. Genet.* **43**, 429–435 (2011).
140. Bertram, L. *et al.* Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. *Am. J. Hum. Genet.* **83**, 623–632 (2008).
141. Trynka, G. *et al.* Disentangling the Effects of Colocalizing Genomic Annotations to

- Functionally Prioritize Non-coding Variants within Complex-Trait Loci. *Am. J. Hum. Genet.* **97**, 139–152 (2015).
142. Raj, T. *et al.* Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. *Science* **344**, 519–523 (2014).
143. Calderon, D. *et al.* Inferring Relevant Cell Types for Complex Traits by Using Single-Cell Gene Expression. *Am. J. Hum. Genet.* **101**, 686–699 (2017).
144. Tansey, K. E., Cameron, D. & Hill, M. J. Genetic risk for Alzheimer's disease is concentrated in specific macrophage and microglial transcriptional networks. *Genome Med.* **10**, 14 (2018).
145. Bolmont, T. *et al.* Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. *J. Neurosci.* **28**, 4283–4292 (2008).
146. Condello, C., Yuan, P., Schain, A. & Grutzendler, J. Microglia constitute a barrier that prevents neurotoxic protofibrillar A β 42 hotspots around plaques. *Nat. Commun.* **6**, 6176 (2015).
147. Hickman, S. E., Allison, E. K. & El Khoury, J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. *J. Neurosci.* **28**, 8354–8360 (2008).
148. Krabbe, G. *et al.* Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. *PLoS One* **8**, e60921 (2013).
149. Spangenberg, E. E. *et al.* Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid- β pathology. *Brain* **139**, 1265–1281 (2016).
150. Hong, S. *et al.* Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science* **352**, 712–716 (2016).
151. Sosna, J. *et al.* Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease. *Mol. Neurodegener.* **13**, 11 (2018).

152. Spangenberg, E. *et al.* Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model. *Nat. Commun.* **10**, 3758 (2019).
153. Asai, H. *et al.* Depletion of microglia and inhibition of exosome synthesis halt tau propagation. *Nat. Neurosci.* **18**, 1584–1593 (2015).
154. Gratuze, M., Leyns, C. E. G. & Holtzman, D. M. New insights into the role of TREM2 in Alzheimer's disease. *Mol. Neurodegener.* **13**, 66 (2018).
155. Zheng, H. *et al.* TREM2 in Alzheimer's Disease: Microglial Survival and Energy Metabolism. *Front. Aging Neurosci.* **10**, 395 (2018).
156. Colonna, M. & Wang, Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. *Nat. Rev. Neurosci.* **17**, 201–207 (2016).
157. Heslegrave, A. *et al.* Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. *Mol. Neurodegener.* **11**, 3 (2016).
158. Zhong, L. *et al.* Soluble TREM2 induces inflammatory responses and enhances microglial survival. *J. Exp. Med.* **214**, 597–607 (2017).
159. Zhong, L. *et al.* Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model. *Nat. Commun.* **10**, 1365 (2019).
160. Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C. & Sheng, M. TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. *Neuron* **91**, 328–340 (2016).
161. Shi, Y. & Holtzman, D. M. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. *Nat. Rev. Immunol.* **18**, 759–772 (2018).
162. Griciuc, A. *et al.* TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease. *Neuron* **103**, 820–835.e7 (2019).
163. Deming, Y. *et al.* The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. *Sci. Transl. Med.* **11**, (2019).
164. Keren-Shaul, H. *et al.* A Unique Microglia Type Associated with Restricting Development

- of Alzheimer's Disease. *Cell* **169**, 1276–1290.e17 (2017).
165. Krasemann, S. *et al.* The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. *Immunity* **47**, 566–581.e9 (2017).
166. Mathys, H. *et al.* Single-cell transcriptomic analysis of Alzheimer's disease. *Nature* (2019) doi:10.1038/s41586-019-1195-2.
167. Smith, A. M. & Dragunow, M. The human side of microglia. *Trends Neurosci.* **37**, 125–135 (2014).
168. Watkins, L. R. & Hutchinson, M. R. A concern on comparing 'apples' and 'oranges' when differences between microglia used in human and rodent studies go far, far beyond simply species: comment on Smith and Dragunow. *Trends in neurosciences* vol. 37 189–190 (2014).
169. Smith, A. M. & Dragunow, M. Response to Watkins and Hutchinson. *Trends Neurosci.* **37**, 190 (2014).
170. Streit, W. J., Braak, H., Xue, Q.-S. & Bechmann, I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. *Acta Neuropathol.* **118**, 475–485 (2009).
171. Gosselin, D. *et al.* An environment-dependent transcriptional network specifies human microglia identity. *Science* **356**, (2017).
172. Olah, M. *et al.* An optimized protocol for the acute isolation of human microglia from autopsy brain samples. *Glia* **60**, 96–111 (2012).
173. Rustenhoven, J. *et al.* Isolation of highly enriched primary human microglia for functional studies. *Sci. Rep.* **6**, 19371 (2016).
174. Mizee, M. R., Poel, M. van der & Huitinga, I. Purification of cells from fresh human brain tissue: primary human glial cells. *Handb. Clin. Neurol.* **150**, 273–283 (2018).
175. Mizee, M. R. *et al.* Isolation of primary microglia from the human post-mortem brain: effects of ante- and post-mortem variables. *Acta Neuropathol Commun* **5**, 16 (2017).

176. Richardson, G. M., Lannigan, J. & Macara, I. G. Does FACS perturb gene expression? *Cytometry A* **87**, 166–175 (2015).
177. Gautier, E. L. *et al.* Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. *Nat. Immunol.* **13**, 1118–1128 (2012).
178. Butovsky, O. *et al.* Identification of a unique TGF- β -dependent molecular and functional signature in microglia. *Nat. Neurosci.* **17**, 131–143 (2014).
179. Olah, M. *et al.* A transcriptomic atlas of aged human microglia. *Nat. Commun.* **9**, 539 (2018).
180. van der Poel, M. *et al.* Transcriptional profiling of human microglia reveals grey-white matter heterogeneity and multiple sclerosis-associated changes. *Nat. Commun.* **10**, 1139 (2019).
181. Hwang, B., Lee, J. H. & Bang, D. Single-cell RNA sequencing technologies and bioinformatics pipelines. *Exp. Mol. Med.* **50**, 96 (2018).
182. Chen, G., Ning, B. & Shi, T. Single-Cell RNA-Seq Technologies and Related Computational Data Analysis. *Front. Genet.* **10**, 317 (2019).
183. Zhong, S. *et al.* A single-cell RNA-seq survey of the developmental landscape of the human prefrontal cortex. *Nature* **555**, 524–528 (2018).
184. Del-Aguila, J. L. *et al.* A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. *Alzheimers. Res. Ther.* **11**, 71 (2019).
185. Olah, M. *et al.* A single cell-based atlas of human microglial states reveals associations with neurological disorders and histopathological features of the aging brain. *bioRxiv* 343780 (2018) doi:10.1101/343780.
186. Masuda, T. *et al.* Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. *Nature* **566**, 388–392 (2019).
187. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **126**, 663–676 (2006).

188. Maherali, N. *et al.* Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. *Cell Stem Cell* **1**, 55–70 (2007).
189. Takahashi, K. *et al.* Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* **131**, 861–872 (2007).
190. Yu, J. *et al.* Induced pluripotent stem cell lines derived from human somatic cells. *Science* **318**, 1917–1920 (2007).
191. Sternecker, J. L., Reinhardt, P. & Schöler, H. R. Investigating human disease using stem cell models. *Nat. Rev. Genet.* **15**, 625–639 (2014).
192. Karlsson, K. R. *et al.* Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3. *Exp. Hematol.* **36**, 1167–1175 (2008).
193. van Wilgenburg, B., Browne, C., Vowles, J. & Cowley, S. A. Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions. *PLoS One* **8**, e71098 (2013).
194. Alasoo, K. *et al.* Transcriptional profiling of macrophages derived from monocytes and iPS cells identifies a conserved response to LPS and novel alternative transcription. *Sci. Rep.* **5**, 12524 (2015).
195. Zhang, H. *et al.* Functional analysis and transcriptomic profiling of iPSC-derived macrophages and their application in modeling Mendelian disease. *Circ. Res.* **117**, 17–28 (2015).
196. Itskovitz-Eldor, J. *et al.* Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. *Mol. Med.* **6**, 88–95 (2000).
197. Muffat, J. *et al.* Efficient derivation of microglia-like cells from human pluripotent stem cells. *Nat. Med.* **22**, 1358–1367 (2016).
198. Abud, E. M. *et al.* iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases. *Neuron* **94**, 278–293.e9 (2017).
199. Douvaras, P. *et al.* Directed Differentiation of Human Pluripotent Stem Cells to Microglia.

- Stem Cell Reports* **8**, 1516–1524 (2017).
200. Brownjohn, P. W. *et al.* Functional Studies of Missense TREM2 Mutations in Human Stem Cell-Derived Microglia. *Stem Cell Reports* **10**, 1294–1307 (2018).
201. McQuade, A. *et al.* Development and validation of a simplified method to generate human microglia from pluripotent stem cells. *Mol. Neurodegener.* **13**, 67 (2018).
202. Haenseler, W. *et al.* A Highly Efficient Human Pluripotent Stem Cell Microglia Model Displays a Neuronal-Co-culture-Specific Expression Profile and Inflammatory Response. *Stem Cell Reports* **8**, 1727–1742 (2017).
203. Qian, X. *et al.* Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure. *Cell* **165**, 1238–1254 (2016).
204. Ormel, P. R. *et al.* Microglia innately develop within cerebral organoids. *Nat. Commun.* **9**, 4167 (2018).
205. Park, J. *et al.* A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer's disease. *Nat. Neurosci.* **21**, 941–951 (2018).
206. Qian, X. *et al.* Generation of human brain region-specific organoids using a miniaturized spinning bioreactor. *Nat. Protoc.* **13**, 565–580 (2018).
207. Leek, J. T. & Storey, J. D. Capturing heterogeneity in gene expression studies by surrogate variable analysis. *PLoS Genet.* **3**, 1724–1735 (2007).
208. Leek, J. T. *et al.* Tackling the widespread and critical impact of batch effects in high-throughput data. *Nat. Rev. Genet.* **11**, 733–739 (2010).
209. Arora, S., Pattwell, S. S., Holland, E. C. & Bolouri, H. Uncertainty in RNA-seq gene expression data. *bioRxiv* 445601 (2018) doi:10.1101/445601.
210. Young, A., Kumasaka, N., Calvert, F. & Hammond, T. R. A map of transcriptional heterogeneity and regulatory variation in human microglia. *bioRxiv* (2019).
211. Bennett, M. L. *et al.* New tools for studying microglia in the mouse and human CNS. *Proceedings of the National Academy of Sciences* **113**, E1738–E1746 (2016).
212. Satoh, J.-I. *et al.* TMEM119 marks a subset of microglia in the human brain.

- Neuropathology* **36**, 39–49 (2016).
213. Hammond, T. R. *et al.* Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. *Immunity* (2018) doi:10.1016/j.immuni.2018.11.004.
214. Montagne, A. *et al.* Blood-brain barrier breakdown in the aging human hippocampus. *Neuron* **85**, 296–302 (2015).
215. Smith, E. E., Schneider, J. A., Wardlaw, J. M. & Greenberg, S. M. Cerebral microinfarcts: the invisible lesions. *Lancet Neurol.* **11**, 272–282 (2012).
216. Villa, A. *et al.* Sex-Specific Features of Microglia from Adult Mice. *Cell Rep.* **23**, 3501–3511 (2018).
217. Hanamsagar, R. *et al.* Generation of a microglial developmental index in mice and in humans reveals a sex difference in maturation and immune reactivity. *Glia* **66**, 460 (2018).
218. Thion, M. S. *et al.* Microbiome Influences Prenatal and Adult Microglia in a Sex-Specific Manner. *Cell* **172**, 500–516.e16 (2018).
219. Picelli, S. *et al.* Full-length RNA-seq from single cells using Smart-seq2. *Nat. Protoc.* **9**, 171–181 (2014).
220. Jiang, H., Lei, R., Ding, S.-W. & Zhu, S. Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads. *BMC Bioinformatics* **15**, 182 (2014).
221. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
222. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* **30**, 923–930 (2014).
223. Kang, H. M. *et al.* Multiplexed droplet single-cell RNA-sequencing using natural genetic variation. *Nat. Biotechnol.* **36**, 89–94 (2018).
224. Zheng, G. X. Y. *et al.* Massively parallel digital transcriptional profiling of single cells. *Nat. Commun.* **8**, 14049 (2017).

225. Habib, N. *et al.* Massively parallel single-nucleus RNA-seq with DroNc-seq. *Nat. Methods* **14**, 955–958 (2017).
226. Reimand, J. *et al.* g:Profiler—a web server for functional interpretation of gene lists (2016 update). *Nucleic Acids Res.* **44**, W83–W89 (2016).
227. Vela, D. Heparin, an emerging and important player in brain iron homeostasis. *J. Transl. Med.* **16**, 25 (2018).
228. Sköld, M. K., von Gertten, C., Sandberg-Nordqvist, A.-C., Mathiesen, T. & Holmin, S. VEGF and VEGF receptor expression after experimental brain contusion in rat. *J. Neurotrauma* **22**, 353–367 (2005).
229. Krum, J. M., Mani, N. & Rosenstein, J. M. Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injury. *Exp. Neurol.* **212**, 108–117 (2008).
230. Ryu, J. K., Cho, T., Choi, H. B., Wang, Y. T. & McLarnon, J. G. Microglial VEGF receptor response is an integral chemotactic component in Alzheimer's disease pathology. *J. Neurosci.* **29**, 3–13 (2009).
231. Lambert, J.-C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat. Genet.* **45**, 1452–1458 (2013).
232. Ginhoux, F. & Prinz, M. Origin of microglia: current concepts and past controversies. *Cold Spring Harb. Perspect. Biol.* **7**, a020537 (2015).
233. Lyakh, L. A. *et al.* Adenovirus type 5 vectors induce dendritic cell differentiation in human CD14(+) monocytes cultured under serum-free conditions. *Blood* **99**, 600–608 (2002).
234. Muruve, D. A. *et al.* The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. *Nature* **452**, 103–107 (2008).
235. Tsuchiya, S. *et al.* Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). *Int. J. Cancer* **26**, 171–176 (1980).
236. Sundström, C. & Nilsson, K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). *Int. J. Cancer* **17**, 565–577 (1976).

237. Chanput, W., Peters, V. & Wichers, H. THP-1 and U937 Cells. in *The Impact of Food Bioactives on Health: in vitro and ex vivo models* (eds. Verhoeckx, K. et al.) 147–159 (Springer International Publishing, 2015).
238. Daigneault, M., Preston, J. A., Marriott, H. M., Whyte, M. K. B. & Dockrell, D. H. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. *PLoS One* **5**, e8668 (2010).
239. Chanput, W., Mes, J. J. & Wichers, H. J. THP-1 cell line: an in vitro cell model for immune modulation approach. *Int. Immunopharmacol.* **23**, 37–45 (2014).
240. Schildberger, A., Rossmannith, E., Eichhorn, T., Strassl, K. & Weber, V. Monocytes, peripheral blood mononuclear cells, and THP-1 cells exhibit different cytokine expression patterns following stimulation with lipopolysaccharide. *Mediators Inflamm.* **2013**, 697972 (2013).
241. Adati, N., Huang, M.-C., Suzuki, T., Suzuki, H. & Kojima, T. High-resolution analysis of aberrant regions in autosomal chromosomes in human leukemia THP-1 cell line. *BMC Res. Notes* **2**, 153 (2009).
242. Buchrieser, J., James, W. & Moore, M. D. Human Induced Pluripotent Stem Cell-Derived Macrophages Share Ontogeny with MYB-Independent Tissue-Resident Macrophages. *Stem Cell Reports* **8**, 334–345 (2017).
243. Garcia-Reitboeck, P. *et al.* Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis. *Cell Rep.* **24**, 2300–2311 (2018).
244. Gan, X. *et al.* Epigenetically repressing human cytomegalovirus lytic infection and reactivation from latency in THP-1 model by targeting H3K9 and H3K27 histone demethylases. *PLoS One* **12**, e0175390 (2017).
245. Phanstiel, D. H. *et al.* Static and Dynamic DNA Loops form AP-1-Bound Activation Hubs during Macrophage Development. *Mol. Cell* **67**, 1037–1048.e6 (2017).
246. Yeung, A. T. Y. *et al.* Exploiting induced pluripotent stem cell-derived macrophages to

- unravel host factors influencing *Chlamydia trachomatis* pathogenesis. *Nat. Commun.* **8**, 15013 (2017).
247. Zhang, Y. *et al.* Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. *Neuron* **89**, 37–53 (2016).
248. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
249. Hicks, S. C. & Irizarry, R. A. quantro: a data-driven approach to guide the choice of an appropriate normalization method. *Genome Biol.* **16**, 117 (2015).
250. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects Models Using lme4. *Journal of Statistical Software* vol. 67 (2015).
251. Jonsson, T. *et al.* Variant of TREM2 Associated with the Risk of Alzheimer's Disease. *N. Engl. J. Med.* **368**, 107–116 (2013).
252. Guerreiro, R. *et al.* TREM2 Variants in Alzheimer's Disease. *N. Engl. J. Med.* **368**, 117–127 (2013).
253. Nguyen, Q. H. *et al.* Single-cell RNA-seq of human induced pluripotent stem cells reveals cellular heterogeneity and cell state transitions between subpopulations. *Genome Res.* **28**, 1053–1066 (2018).
254. Paik, D. T. *et al.* Large-Scale Single-Cell RNA-Seq Reveals Molecular Signatures of Heterogeneous Populations of Human Induced Pluripotent Stem Cell-Derived Endothelial Cells. *Circ. Res.* **123**, 443–450 (2018).
255. McCracken, I. R. *et al.* Transcriptional dynamics of pluripotent stem cell-derived endothelial cell differentiation revealed by single-cell RNA sequencing. *Eur. Heart J.* (2019) doi:10.1093/eurheartj/ehz351.
256. Etzrodt, M., Endele, M. & Schroeder, T. Quantitative single-cell approaches to stem cell research. *Cell Stem Cell* **15**, 546–558 (2014).
257. Tanay, A. & Regev, A. Scaling single-cell genomics from phenomenology to mechanism.

- Nature* **541**, 331–338 (2017).
258. Saelens, W., Cannoodt, R., Todorov, H. & Saeys, Y. A comparison of single-cell trajectory inference methods. *Nat. Biotechnol.* **37**, 547–554 (2019).
259. Cao, J. *et al.* The single-cell transcriptional landscape of mammalian organogenesis. *Nature* **566**, 496–502 (2019).
260. McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. *arXiv [stat.ML]* (2018).
261. Paonessa, F. *et al.* Microtubules Deform the Nuclear Membrane and Disrupt Nucleocytoplasmic Transport in Tau-Mediated Frontotemporal Dementia. *Cell Rep.* **26**, 582–593.e5 (2019).
262. Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected communities. *Sci. Rep.* **9**, 5233 (2019).
263. Levine, J. H. *et al.* Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. *Cell* **162**, 184–197 (2015).
264. Wolf, F. A. *et al.* PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells. *Genome Biol.* **20**, 59 (2019).
265. Leung, G. A. *et al.* The lymphoid-associated interleukin 7 receptor (IL7R) regulates tissue-resident macrophage development. *Development* **146**, (2019).
266. Grabert, K. *et al.* Microglial brain region-dependent diversity and selective regional sensitivities to aging. *Nat. Neurosci.* **19**, 504–516 (2016).
267. Parakalan, R. *et al.* Transcriptome analysis of amoeboid and ramified microglia isolated from the corpus callosum of rat brain. *BMC Neurosci.* **13**, 64 (2012).
268. Rothe, T. *et al.* The Nuclear Receptor Nr4a1 Acts as a Microglia Rheostat and Serves as a Therapeutic Target in Autoimmune-Driven Central Nervous System Inflammation. *J. Immunol.* **198**, 3878–3885 (2017).
269. Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888–1902.e21 (2019).

270. Eng, C.-H. L. *et al.* Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH. *Nature* **568**, 235–239 (2019).
271. Burgess, D. J. Spatial transcriptomics coming of age. *Nature reviews. Genetics* vol. 20 317 (2019).
272. Wang, X., Park, J., Susztak, K., Zhang, N. R. & Li, M. Bulk tissue cell type deconvolution with multi-subject single-cell expression reference. *Nat. Commun.* **10**, 1–9 (2019).
273. Cakir, B. *et al.* Engineering of human brain organoids with a functional vascular-like system. *Nat. Methods* **16**, 1169–1175 (2019).
274. Phan, D. T. *et al.* Blood-brain barrier-on-a-chip: Microphysiological systems that capture the complexity of the blood-central nervous system interface. *Exp. Biol. Med.* **242**, 1669–1678 (2017).
275. Cuomo, A. S. E. *et al.* Single-cell RNA-sequencing of differentiating iPS cells reveals dynamic genetic effects on gene expression. *bioRxiv* 630996 (2019)
doi:10.1101/630996.
276. McManus, J., Cheng, Z. & Vogel, C. Next-generation analysis of gene expression regulation--comparing the roles of synthesis and degradation. *Mol. Biosyst.* **11**, 2680–2689 (2015).
277. Liu, Y., Beyer, A. & Aebersold, R. On the Dependency of Cellular Protein Levels on mRNA Abundance. *Cell* **165**, 535–550 (2016).
278. Choi, S. H., Kim, Y. H., Quinti, L., Tanzi, R. E. & Kim, D. Y. 3D culture models of Alzheimer's disease: a road map to a 'cure-in-a-dish'. *Mol. Neurodegener.* **11**, 75 (2016).
279. Penney, J., Ralvenius, W. T. & Tsai, L.-H. Modeling Alzheimer's disease with iPSC-derived brain cells. *Mol. Psychiatry* (2019) doi:10.1038/s41380-019-0468-3.
280. Wray, N. R., Goddard, M. E. & Visscher, P. M. Prediction of individual genetic risk to disease from genome-wide association studies. *Genome Res.* **17**, 1520–1528 (2007).